Xenon制药 XENE 深 沪
等待开盘 11-03 09:30:00 美东时间
41.92
-0.750
-1.76%
华盛通- 最 高42.72
- 今 开42.26
- 成交量 76.61万股
- 最 低 41.45
- 昨 收 42.67
- 总市值 32.32亿
- 52周最高 45.45
- 市盈率 静 --
- 换手率 0.99%
- 52周最低 26.74
- 委 比 81.68%
- 总股本 7710.58万
- 历史最高 50.99
- 量 比 0.96
- 振 幅 2.98%
- 历史最低 2.10
- 每 手 1
- 风险率 4.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 3, 2025
Companies Reporting Before The Bell • CNA Financial (NYSE:CNA) is expected to r...
22分钟前
Xenon appoints Tucker Kelly as CFO
Xenon Pharmaceuticals (NASDAQ:XENE) announced on Thursday the appointment of Tucker Kelly as Chief Financial Officer and member of the Xenon senior executive team. Kelly is an executive who brings e...
10-16 20:48
Xenon Pharmaceutical Appoints Tucker Kelly CFO, Effective Oct. 15, 2025
VANCOUVER, British Columbia and BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and
10-16 20:32
美股大行评级 | 最高300美元，AMD获多家大行上调目标价！
今日重点评级关注：Maxim Group：维持Gain Therapeutics"买入"评级，目标价从5美元升至7美元；HC Wainwright & Co.：维持Icecure Medical"买入"评级，目标价从2美元升至2.5美元
10-08 09:14
Chardan Capital Maintains Buy on Xenon Pharmaceuticals, Maintains $55 Price Target
Chardan Capital analyst Rudy Li maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Buy and maintains $55 price target.
10-07 19:45
Goldman's 48 potential M&A candidates
Deal activity will rise by 15% in 2026, according to Goldman Sachs. Strategist David Kostin says M&A activity will increase next year "alongside accelerating US economic growth, improving CEO confiden...
09-29 03:14
Xenon Announces Upcoming Investor Webinar to Discuss Early-Stage Ion Channel Programs for the Potential Treatment of Pain
Xenon Pharmaceuticals will host an investor webinar on October 6, 2025, to discuss its early-stage programs targeting Kv7 and Nav1.7 for non-opioid pain treatments. The webinar, titled "Developing Novel Non-Opioid Treatments for Pain," will run from 11:30 AM to 12:30 PM Eastern Time. Investors can register via the provided link and submit questions during the session or beforehand. A replay will be available on the company's website after the eve...
09-25 20:01
RBC Capital Reiterates Outperform on Xenon Pharmaceuticals, Maintains $55 Price Target
RBC Capital analyst Brian Abrahams reiterates Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and maintains $55 price target.
09-02 21:30
美股大行评级 | 潜在涨幅921.1%！Intensity Therapeutics获Brookline Capital升级至"买入"，目标价上调至3美元
今日重点评级关注：Brookline Capital：上调Intensity Therapeutics评级至"买入"，目标价3美元；Chardan Capital：维持Taysha Gene Therapies"买入"评级，目标价从9美元升至10美元
08-13 09:10
Wedbush Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $43
Wedbush analyst Laura Chico maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $42 to $43.
08-12 21:27
